ESC 365 - Expanding therapeutic options for lowering LDL-c: Where will bempedoic acid and inclisiran contribute.

Open Access

Expanding therapeutic options for lowering LDL-c: Where will bempedoic acid and inclisiran contribute.

Session: Redefining intensive LDL-c management in high risk patients: The case for combination therapy

Topic: Risk Factors and Prevention

Speaker: Doctor C. Ballantyne (Houston, US)

Sponsored by PACE-CME

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)

22 presentations

2 followers

3 more presentations in this session

LDL-c in the management of high CV risk: Changing the paradigm for prevention.

Speaker: Professor K. Ray (London, GB)

The urgency to treat LDL-c post MI: The role of PCSK9 mAbs in reaching goals.

Speaker: Professor D. Connolly (Birmingham, GB)

Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?

Speaker: Professor J. Kastelein (Amsterdam, NL)

Access the full session

Redefining intensive LDL-c management in high risk patients: The case for combination therapy

Speakers: Doctor C. Ballantyne, Professor K. Ray, Professor D. Connolly, Professor J. Kastelein

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by